Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

• ClinicalTrials.gov Identifier: NCT01465997
• Recruitment Status: Completed
• First Posted: November 7, 2011
• Results First Posted: August 2, 2017
• Last Update Posted: July 18, 2018
• Sponsor: UCB BIOSCIENCES GmbH
• Collaborator: Eden Sarl
• Information provided by (Responsible Party): UCB Pharma ( UCB BIOSCIENCES GmbH )

Study Description

Brief Summary:

Compare safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with primary safety variables including spontaneous reports of Adverse Events (AEs), withdrawal of subjects due to AEs, reporting of Serious AEs (SAEs).

Condition or disease	Intervention/treatment	Phase
Epilepsy; Monotherapy	Drug: Lacosamide; Drug: Carbamazepine-Controlled Release (CBZ-CR)	Phase 3

Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial.   More info ...

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 551 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
• Study Start Date: May 2012
• Actual Primary Completion Date: January 2017
• Actual Study Completion Date: January 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Lacosamide; 50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)	Drug: Lacosamide; 50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years); Other Name: VIMPAT film-coated tablets
Active Comparator: Carbamazepine-Controlled Release (CBZ-CR); 200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum of 3.5 Years)	Drug: Carbamazepine-Controlled Release (CBZ-CR); 200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years); Other Name: Tegretol® Retard Tablets 200 mg

Outcome Measures

Primary Outcome Measures :

1. Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (Maximum of 3.5 Years) [ Time Frame: Up to 3.5 Years (Duration of the Treatment Phase) ]
   Treatment-emergent AEs were defined as those events which started on or after the date of first dose of SP0994 study medication, or events in which severity worsened on or after the date of first dose of SP0994 study medication. AEs which occurred within 30 days after last dose of study medication were considered treatment emergent.
2. Number of Subjects Who Withdrew From the Study Due to a Treatment-emergent Adverse Event (AE) During the Treatment Phase (Maximum 3.5 Years) [ Time Frame: Up to 3.5 Years (Duration of the Treatment Phase) ]
   Treatment-emergent AEs were defined as those events which started on or after the date of first dose of SP0994 study medication, or events in which severity worsened on or after the date of first dose of SP0994 study medication. AEs which occurred within 30 days after last dose of study medication were considered treatment emergent.
3. Number of Subjects With at Least One Treatment-emergent Serious Adverse Event (SAE) During the Treatment Phase (Maximum of 3.5 Years) [ Time Frame: Up to 3.5 Years (Duration of the Treatment Phase) ]
   A Serious Adverse Event is any untoward medical occurrence that at any dose results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity is a congenital anomaly/birth defect.

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subject/legal representative is considered reliable and capable of adhering to the protocol
• Subject has remained seizure free and completed the Maintenance Phase of the SP0993; or subject has experienced 1 or more seizures on the first or second target dose during the SP0993 Maintenance Phase
• Subject is expected to benefit from participation in SP0994 in the opinion of the investigator

Exclusion Criteria:

• Subject is receiving any investigational drugs or using any experimental devices in addition to LCM or CBZ-CR
• Subject experienced a seizure at the third target dose during the Evaluation Phase or Maintenance Phase of the SP0993 study
• Subject is taking benzodiazepines for a non-epilepsy indication
• Subject meets a withdrawal criterion from the previous study SP0993
• Subject is experiencing an ongoing SAE from the previous study SP0993
• Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening. Or subject has a positive response (Yes) to either Question 4 or Question 5 of the C-SSRS at Screening in the "Since Last Visit" version

Contacts and Locations

  Show 150 Study Locations

Sponsors and Collaborators

UCB BIOSCIENCES GmbH

Eden Sarl

Investigators

• Study Director: UCB Cares; +1 877 822 9493 (UCB)

More Information

Additional Information:

Product Information  FDA Safety Alerts and Recalls 

• Responsible Party: UCB BIOSCIENCES GmbH
• ClinicalTrials.gov Identifier: NCT01465997 History of Changes
• Other Study ID Numbers: SP0994; 2010-021238-74 ( EudraCT Number )
• First Posted: November 7, 2011
• Results First Posted: August 2, 2017
• Last Update Posted: July 18, 2018
• Last Verified: September 2017

Keywords provided by UCB Pharma ( UCB BIOSCIENCES GmbH ):

Lacosamide

Additional relevant MeSH terms:

Carbamazepine; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 Enzyme Inducers; Epilepsy; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Lacosamide; Anticonvulsants; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Antimanic Agents; Tranquilizing Agents; Central Nervous System Depressants; Physiological Effects of Drugs; Psychotropic Drugs; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents